COLLAGENASE IN THE TREATMENT OF DUPUYTREN'S DISEASE

胶原酶治疗掌腱膜挛缩症

• 批准号: 6283030
• 负责人: LAWRENCE C HURST
• 金额: $ 2.44万
• 依托单位: STATE UNIVERSITY NEW YORK STONY BROOK
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-06-04 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6283030
• 关键词: clinical research; collagenase; connective tissue; connective tissue disorder; connective tissue disorder chemotherapy; contracture; enzyme therapy; fingers; human subject; human therapy evaluation; limb movement

The aim of this study is to test the Phase 2 clinical efficacy of Clostridial collagenase as a non-operative (injectable) treatment for residual stage Dupuytren's disease. We propose to test whether Clostridial collagenase when infected into a pathological cord a. near the metacarpophalangeal join (MP), or b. near the proximalinterphalangeal joint (PIP) or c. near both the metacarpophalangeal joint (MP) and the proximalinterphalangeal joint (PIP) of residual stage Dupuytren's patients, will rupture the pathologic collagen cord upon active finger extension. A dose escalation scheme will be employed for cord rupture. Following cord rupture by collagenase, we will test if normal range of finger motion and normal grip strength is obtained and maintained in follow-up and that the disease will not recur with a frequency that is unacceptable based on the natural history of disease recurrence.

本研究的目的是测试ii期临床疗效